Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$558.87 USD
+13.41 (2.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $559.71 +0.84 (0.15%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
For Regeneron Pharmaceuticals, Inc., the company has a dividend yield of 0.65% compared to the Medical - Biomedical and Genetics industry's median yield of zero percent.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
REGN 558.87 +13.41(2.46%)
Will REGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nonfarm Payrolls Come in SIgnificantly Below Expectations
Jobs Shrink in the Summer of '25, Pre-Markets Lower
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for REGN
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
Regeneron (REGN) Reports Strong Q2 2025 Driven by Key Products
Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Regeneron (REGN) Price Target Cut Amid Eylea Performance Concerns